Lucy Day sold $3,965 of ANTX
Chief Financial Officer at AN2 Therapeutics, Inc.. 2,957 shares at an average of $1.34, traded Jan 3, 2025, filed Jan 7, 2025.
Score components
- +22RoleCFO
- 0Trade size$4k at market
- 0Share of holdings soldSold 8.3% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-003160, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 3, 2025 | SOpen-market sale Common Stock | -2,957 | $1.34 | $3,965 | 32,670 | Jan 7, 2025 |
Related signals
Other insiders at AN2 Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | AN2 Therapeutics, Inc. | Robin Shane Readnour director | $6,675 1,108 shares | -0% | |
| 13Weak | AN2 Therapeutics, Inc. | Robin Shane Readnour director | $97k 16,119 shares | -3% | |
| 23Weak | AN2 Therapeutics, Inc. | Sarah Joanne Williams Principal Accounting Officer | $1,504 272 shares | -0% | |
| 21Weak | ANTXbuy AN2 Therapeutics, Inc. | Margaret M FitzPatrick director | $12k 2,098 shares | +24% | |
| 23Weak | AN2 Therapeutics, Inc. | Stephen David Prior Chief Strategy Officer | $872 765 shares | -1% | |
| 23Weak | AN2 Therapeutics, Inc. | Joshua M Eizen See Remarks | $3,214 2,819 shares | -2% | |
| 24Weak | ANTXsell AN2 Therapeutics, Inc. | Braden Michael Leonard owner | $218k 200,000 shares | -6% | |
| 51Moderate | AN2 Therapeutics, Inc. | Eric Easom Chief Executive Officer | $11k 10,000 shares | +4% | |
| 47Moderate | ANTXsell AN2 Therapeutics, Inc. | Braden Michael Leonard owner | $2.9M 2,532,000 shares | -44% | |
| 39Weak | AN2 Therapeutics, Inc. | Margaret M FitzPatrick director | $10k 8,610 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.